






































Copyright © 2020 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Critical Care Medicine www.ccmjournal.org     1
DOI: 10.1097/CCM.0000000000004747
Copyright © 2020 The Author(s). 
Published by Wolters Kluwer Health, 
Inc. on behalf of the Society of 
Critical Care Medicine and Wolters 
Kluwer Health, Inc. This is an open 
access article distributed under 
the Creative Commons Attribution 
License 4.0 (CCBY), which permits 
unrestricted use, distribution, and re-
production in any medium, provided 
the original work is properly cited. 
OBJECTIVES: To measure temporal trends in survival over time in people 
with severe coronavirus disease 2019 requiring critical care (high depend-
ency unit or ICU) management, and to assess whether temporal variation 
in mortality was explained by changes in patient demographics and comor-
bidity burden over time.
DESIGN: Retrospective observational cohort; based on data reported to 
the COVID-19 Hospitalisation in England Surveillance System. The pri-
mary outcome was in-hospital 30-day all-cause mortality. Unadjusted sur-
vival was estimated by calendar week of admission, and Cox proportional 
hazards models were used to estimate adjusted survival, controlling for 
age, sex, ethnicity, major comorbidities, and geographical region.
SETTING: One hundred eight English critical care units.
PATIENTS: All adult (18 yr +) coronavirus disease 2019 specific critical 
care admissions between March 1, 2020, and June 27, 2020.
INTERVENTIONS: Not applicable.
MEASUREMENTS AND MAIN RESULTS: Twenty-one thousand 
eighty-two critical care patients (high dependency unit n = 15,367; ICU 
n = 5,715) were included. Unadjusted survival at 30 days was lowest for 
people admitted in late March in both high dependency unit (71.6% sur-
vival) and ICU (58.0% survival). By the end of June, survival had improved 
to 92.7% in high dependency unit and 80.4% in ICU. Improvements in 
survival remained after adjustment for patient characteristics (age, sex, eth-
nicity, and major comorbidities) and geographical region.
CONCLUSIONS: There has been a substantial improvement in survival 
amongst people admitted to critical care with coronavirus disease 2019 
in England, with markedly higher survival rates in people admitted in May 
and June compared with those admitted in March and April. Our analysis 
suggests this improvement is not due to temporal changes in the age, sex, 
ethnicity, or major comorbidity burden of admitted patients.
KEY WORDS: coronavirus infection; critical care; hospital mortality; 
public health surveillance; quality of healthcare
Recent national data from England suggests there has been an improve-ment in the survival of patients hospitalized with coronavirus disease 2019 (COVID-19) over recent months, with an estimated decline in 
the case-fatality rate of hospitalized patients from 6% in early April to 1.5% by 
mid-June (1). One potential explanation for this observation is a shift in the 
demographics of people admitted with COVID-19 toward younger and overall 
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less comorbid individuals, resulting in improved sur-
vival. Another possibility is that expanded in-hospital 
testing to facilitate cohorting of potentially asymp-
tomatic cases has led to increased identification of 
milder cases as the pandemic has progressed (2); in 
the early stages of the pandemic, it was not nation-
ally mandated that all hospitalized patients were rou-
tinely tested. If the latter is a significant factor in the 
declining mortality, then we would expect mortality 
in the critical care setting to have remained relatively 
unchanged.
We sought to test whether the same trend of 
improving survival over time has been seen in people 
with severe COVID-19 requiring critical care (high 
dependency unit [HDU] or ICU) management, 
whether improving survival reflected changes in pa-
tient demographics, and whether time trends varied 
by demographics and geography in England.
MATERIALS AND METHODS
Data Source
We accessed national data from the COVID-19 
Hospitalisation in England Surveillance System 
(CHESS) (3), a statutory collection of all individuals 
with confirmed or clinically presumed COVID-19 
managed in HDU or ICU. CHESS data were extracted 
on July 27, 2020, at which time point 108 National 
Health Service (NHS) trusts had reported to CHESS 
(each NHS trust may comprise more than one hos-
pital). Our study period was March 1 until June 27, 
meaning every patient had 30 days of potential fol-
low-up available after being admitted to hospital. 
People 18–99 years old were eligible, pregnant women 
(n = 88) were excluded. Two cohorts were defined as 
follows: 1) all people admitted to HDU but never ICU 
and 2) all people admitted to ICU.
Recorded Clinical Features
CHESS contains individual-level demographic char-
acteristics: age, sex, ethnicity, admitting hospital, and 
recorded comorbidities (obesity; diabetes; asthma; 
chronic respiratory disease; chronic heart disease; 
hypertension; immunosuppression due to disease or 
treatment; chronic neurologic disease; chronic renal 
disease; and chronic liver disease). We coded ethnicity 
as White, Asian, Black, mixed, and other; categorized 
hospital centers by region: London, East of England, 
Midlands, North East, and Yorkshire, North West, 
South East, and South West; and recorded comorbidi-
ties as binary “No/Yes” variables.
Statistical Analysis
The primary outcome was in-hospital all-cause mor-
tality in the 30 days after hospital admission. Patients 
discharged alive or transferred prior to 30 days were 
assumed to be alive at 30 days (4). We estimated un-
adjusted survival for each week of the study period 
(17 wk in total, from the week of March 1, 2020, to 
the week of June 21, 2020) as 1–(number of deaths 
for patients admitted that week/total number of 
critical care admissions that week). We estimated 
adjusted hazard ratios (HRs) for mortality by week of 
admission (categorical variable, with the week start-
ing March 29, the week of peak critical care admis-
sions, used at the reference week) using separate Cox 
proportional hazards models for the HDU and ICU 
cohorts, adjusting for age (three-knot nonlinear re-
stricted cubic spline), sex, ethnicity, comorbidities, 
and geographical region, with proportional hazards 
assumptions tested. For the ICU cohort, follow-up 
began at the date of ICU admission, with additional 
adjustment for the number of days from hospital to 
ICU admission (to capture possible changes in ad-
mission policy over time, for example, if there were 
delays in admitting patients to ICU earlier in the 
pandemic in the United Kingdom when concern over 
hospital capacity was greatest). After initial analysis 
modeling week of admission as a categorical vari-
able, we ran additional models to estimate the av-
erage change in survival, per week, for the period of 
the week of March 29, 2020, to the week of June 21, 
2020, by updating the same adjusted models but with 
week of admission fitted as a continuous linear term. 
As sensitivity analysis, we repeated models with NHS 
hospital trust included as a random effect. Analyses 
were conducted with R (Version 3.6.2 [5]), including 
use of the packages survival, rms and coxme.
Ethics and Governance
The study was reviewed and approved by the Warwick 
Biosciences Research Ethics Committee (BSREC 
119/19-20-V1.1) and sponsorship is being provided by 
University of Warwick (SOC.28/19-20).
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RESULTS
Twenty-one–thousand eighty-two individuals (HDU 
n = 15,367; ICU n = 5,715) were eligible for the study, 
of whom 5,484 (26.0%) died (HDU n = 3,438 [22.3%]; 
ICU n = 2,046 [35.8%]). Fifty-six percent of people 
admitted to HDU were male (mean age 70), compared 
with 71% male in ICU (mean age 58); full recorded 
characteristics are reported in sTable 1 (Supplemental 
Digital Content 1, http://links.lww.com/CCM/F976).
Unadjusted survival was lowest for people admitted 
in early March in both HDU (28.4% for people admit-
ted the week of March 22) and ICU (42.0% for those 
admitted during the week of March 15) (Fig. 1; for un-
derlying data,  sTable 2, Supplemental Digital Content 
1, http://links.lww.com/CCM/F976). After the week 
of March 29, unadjusted survival improved for people 
admitted to both HDU and ICU.
Improvements in survival after the week of March 
29 were still observed after adjustment for patient 
characteristics (age, sex, ethnicity, and comorbidities) 
and geographical region (Fig. 2A; for underlying data, 
sTable 3, Supplemental Digital Content 1, http://links.
lww.com/CCM/F976). Relative to patients admitted 
during the week of March 29, survival improved by 
12.7% per week in HDU (adjusted HR for mortality, 
0.87; 95% CI, 0.86–0.89), and 8.9% in ICU (adjusted 
HR, 0.91; 95% CI, 0.89–0.93) up to the week of June 
21, 2020 (Fig. 2A). Results were consistent with NHS 
hospital trust as an additional random effect.
The improvement in survival relative to the week of 
March 29 was consistent across subgroups defined by 
age, sex, ethnicity, and in people with major comor-
bidities (Fig. 2B). Improvements were consistent by 
geographical region, except for in the North East and 
Yorkshire, where there was evidence of an improve-
ment in HDU but not ICU (Fig. 2B).
DISCUSSION
Our analysis, using a large national COVID-19 spe-
cific critical care database capturing information on 
hospital admissions up to July 27, 2020, shows a sub-
stantial recent improvement in survival for people 
admitted to critical care with COVID-19 in England, 
with markedly improved survival for people admit-
ted after mid-April compared with earlier in the pan-
demic. Adjustment for age, sex, ethnicity, and major 
comorbidities suggests this 
improvement may not re-
flect a change in patient 
background characteris-
tics. Similarly, adjustment 
for geographical region 
means temporal variation 
in critical care admissions 
across the country does 
not offer an explanation for 
our findings.
A survival improve-
ment was observed for 
all regions in England in 
both HDU and ICU set-
tings, although in the 
North East and Yorkshire, 
an improvement was only 
seen in patients admitted 
to HDU. A recent anal-
ysis of the CHESS data-
set matched with national 
level audit data demon-
strated a marked variation 
in survival by hospital 
Figure 1. Unadjusted estimates of the proportion of patients surviving for 30 d after critical 
care admission, by week of admission, from the week of March 1, 2020, to the week of June 21, 
2020. Point estimates are calculated as, for each week, 1–(number of deaths/number of hospital 
admissions). Error bars represent 95% CIs. HDU = high intensive unit.
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trust for patients admitted to ICU that 
was not explained by severity profile 
(as assessed by Acute Physiology and 
Chronic Health Evaluation II score) of 
those admitted (6). The combination of 
these two results suggests that further 
study is warranted to understand differ-
ences in survival by hospital and geo-
graphical region across England.
In this study, we included patients 
from 108 out of 140 potential trusts in 
England reporting to CHESS by June 
27, 2020. As such, there are unsurpris-
ingly differences in the study popula-
tion compared with that captured by the 
U.K.’s Intensive Care National Audit and 
Research Centre (ICNARC), the other 
national clinical audit of COVID-19 
critical care admissions. ICNARC 
includes intensive care and combined 
intensive care/high dependency unit 
admissions (across Wales and Northern 
Ireland as well as England), while 
CHESS, a collection of all high depend-
ency unit and ICU admissions, captures 
a broader inpatient population but is 
restricted to England. A comparison 
of the temporal trends observed in the 
CHESS ICU subgroup is similar to that 
of a recent (as of yet not peer-reviewed) 
report from ICNARC showing a sub-
stantial drop in odds of mortality over 
the course of the first wave (i.e., odds 
ratio 0.70 [0.61–0.81], for post-peak vs 
pre-pandemic, and 0.97 [0.86–1.08] for 
peak vs pre-pandemic) (7); however, 
our analysis extends this observation to 
the HDU setting thereby demonstrating 
that this effect is likely to be robust to 
the selection bias implicit in identifying 
candidates for intensivist care.
A potential limitation of this anal-
ysis is the possibility of reporting delays 
leading to incomplete ascertainment of 
death in more recent weeks, although 
this was mitigated by our study design, 
which focused on in-hospital mortality 
and ensured all eligible patients had 
Figure 2. A, Adjusted hazard ratios (HRs) representing the relative change over 
time in-hospital mortality for people admitted to HDU and ICU with coronavirus 
disease 2019 (COVID-19) in England, up to the week of June 21, 2020. Bars 
represent 95% CIs. A, Relative mortality by week of hospital admission. An HR less 
than 1 reflects a lower mortality compared to patients admitted the week 
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at least 30 days follow-up available. While reporting 
delays might plausibly lead to under-ascertainment 
of mortality for people admitted in May, a clear mor-
tality improvement was also observed in April. As 
CHESS is a daily mandatory collection for all hospitals 
in England, we would expect reasonably accurate and 
timely capture of in-hospital mortality, and so feel it is 
unlikely our findings simply reflect reporting delays.
Temporal changes in COVID-19 disease severity at 
admission, patient selection for critical care manage-
ment, critical care treatment, hospital capacity, and 
COVID-19 testing all offer potential explanations for 
our findings. Of particular note regarding treatment, 
the RECOVERY trial began nationwide recruitment 
in early April, and included dexamethasone which 
was later shown to have mortality-specific, or length 
of intensive treatment unit admission-specific ben-
efits, as well as azithromycin, tocilizumab, and con-
valescent plasma (8). Randomised Evaluation of 
COVID-19 Therapy (RECOVERY) did not include 
remdesivir, also shown to have therapeutic benefit in 
COVID-19 patients, but did not exclude patients re-
ceiving remdesivir or other potential COVID-19 treat-
ments from the trial itself (9). It is, therefore, plausible 
recruitment to RECOVERY might partially explain 
improved patient outcomes, although we lacked data 
on medications administered in hospital to evaluate 
this. Regarding capacity, it has been shown that bed 
saturation across England was at its highest in early 
April and then progressively improved over the course 
of the first wave of the pandemic (10). Therefore, the 
observed time trend could be a manifestation of the 
well-established decline in patient-specific outcomes 
often observed at “unsafe” occupancy levels (11). 
Further interrogation of possible quality-of-care based 
explanations is required.
In conclusion, there has been a substantial mortality 
improvement in people admitted to critical care with 
COVID-19 in England, with markedly lower mortality 
in people admitted in mid-April and May compared 
with earlier in the pandemic. This trend remains after 
adjustment for patient demographics and comorbidi-
ties, suggesting this improvement is not due to chang-
ing patient characteristics. Possible causes include 
the introduction of effective treatments as part of the 
RECOVERY trial, improved physician understanding 
of the disease process, and a falling critical care burden.
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Data cannot be shared publicly as it was collected by Public 
Health England (PHE) as part of their statutory responsibilities, 
which allows them to process patient confidential data without 
Figure 2. (Continued). commencing March 29, 2020, which 
was used as the reference week as it was the peak week of 
COVID-19 admissions in COVID-19 Hospitalisation in England 
Surveillance System (CHESS). B, Average change in relative 
mortality per week, from the week of March 29, 2020, to the 
week of June 21, 2020, overall and for subgroups of patients. An 
HR less than 1 reflects a survival improvement. This figure shows 
that, for all patients, compared to people admitted during the 
week of March 29, 2020, for each subsequent week there was a 
12.7% relative improvement in survival for high dependency unit 
(HDU) treated patients (adjusted HR for mortality 0.87 [95% CI 
0.86-0.89]), and an 8.9% improvement in ICU treated patients 
(adjusted HR 0.91 [95% CI 0.89-0.93]). Similar improvements 
were seen across all age subgroups, in both men and women, 
and in people of White and Asian ethnicity. *HRs for mixed and 
other ethnicity defined subgroups not reported due to low patient 
numbers.
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explicit patient consent. Data utilized in this study were made 
available through an agreement between the University of 
Warwick and PHE. Individual requests for access to COVID-19 
Hospitalisation in England Surveillance System data are consid-
ered directly by PHE (contact via covid19surv@phe.gov.uk). All 
the code utilized has been archived at the following link: https://
github.com/vollmersj/COVID19TimeTrend.
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